Document is current

Article History

Received: 10 April 2026

Accepted: 15 May 2026

First Online: 5 June 2026

Declarations

:

: Luigi Gargiulo has been a consultant and/or speaker and has served as an advisory board member for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Galderma, Johnson and Johnson, Incyte, LEO Pharma, Novartis, Pierre Fabre, Pfizer, Sanofi, and UCB Pharma. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Angelo V. Marzano has conflict of interest with AbbVie, Boehringer Ingelheim, Bristol Myers, Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi and UCB. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Federico Bardazzi has been a consultant adviser and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene, and Janssen. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Eli Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma. Andrea Carugno has been a consultant and/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma, and Boehringer Ingelheim. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Eli Lilly, and Leo Pharma. Anna Campanati has served as a speaker, consultant, or advisory board member for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte, Leo Pharma, Merck Sharp & Dohme, Janssen-Cilag, Novartis, Pfizer, Regeneron, Sanofi-Aventis, and UCB Pharma. Claudio Guarneri has been a scientific consultant, speaker, and clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma. Emanuele Trovato is involved in an intermittent project focused on consulting and/or advisory relationships and/or travel-congress support with Eli Lilly, Novartis, Janssen-Cilag, AbbVie, and Almirall. Marina Venturini served as a speaker or advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. Francesco Loconsole served on advisory boards and/or received honoraria for lectures from Abbvie, Janssen-Cilag, Novartis, Lilly, Sanofi. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Diego Orsini has been a speaker and/or consultant for AbbVie, Leo Pharma, UCB, Bristol-Myers Squibb, and Boehringer Ingelheim. Simone Ribero has served as an advisory board member and/or consultant and has received fees and speaker’s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Giampiero Girolomoni, Giovanni Pappagallo, Stefano Piaserico, Andrea Conti, Valentina Dini and Nicoletta Bernardini have nothing to disclose. Anna Campanati and Diego Orsini are Editorial Board members of Dermatology and Therapy. Anna Campanati and Diego Orsini were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Institutional review board approval was exempted for this study as its procedures did not include human subjects and did not deviate from good clinical practice. All the involved dermatologists gave their approval for the study to be published. All the dermatologists who were part of the consensus were involved in the writing and/or revision of the manuscript. All the dermatologists who participated in the consensus were aware of the objective of the study, and they all knew that the manuscript would be published. The participants gave written informed consent.